92292-84-7

Usage

Uses

Different sources of media describe the Uses of 92292-84-7 differently. You can refer to the following data:
1. 4-Acetoxy-N,N-dimethyltryptamine, is a Psilocin related compound, and It would seem to be an ideal prodrug to replace Psilocybin in future clinical studies, since Psilocin is the principal metabolite of Psilocibin.Controlled substance (hallucinogen).
2. 4-Acetoxy-N,N-dimethyltryptamine, is a Psilocin (P839630) related compound, and It would seem to be an ideal prodrug to replace Psilocybin in future clinical studies, since Psilocin is the principal metabolite of Psilocibin.Controlled substance (hallucinogen).

InChI:InChI=1/C14H18N2O2/c1-10(17)18-13-6-4-5-12-14(13)11(9-15-12)7-8-16(2)3/h4-6,9,15H,7-8H2,1-3H3

Upstream product

• 520-53-6 psilocin 
• 75-36-5 acetyl chloride 
• 952006-34-7 3-(2-chloro-2-oxoacetyl)-1H-indol-4-yl acetate 
• 30000-66-9 3-[2-(dimethylamino)-2-oxoacetyl]-1H-indol-4-yl acetate 
• 52061-51-5 4-Benzyloxyindol-3-yl-N,N-dimethylglyoxylamide 
• 20289-26-3 4-benzyloxy-1H-indole 
• 28383-23-5 2-(4-(benzyloxy)-1H-indol-3-yl)-N,N-dimethylethan-1-amine 
• 108-24-7 acetic anhydride 

Downstream Products

• 520-53-6 psilocin 

Relevant academic research and scientific papers

Improvements to the synthesis of psilocybin and a facile method for preparing the O-acetyl prodrug of psilocin

An improved procedure to accomplish the O-phosphorylation of 4-hydroxy- N,N-dimethyltryptamine (psilocin 5) is reported that utilizes reaction between the O-lithium salt of 5 and tetra-O-benzylpyrophosphate. The O- benzyl groups were removed by catalytic hydrogenation over palladium on carbon to afford N,N-dimethyl-4-phosphoryloxytryptamine (psilocybin, 1). In view of difficulties encountered in the preparation of 1, it is suggested that 4-acetoxy-N,N-dimethyltryptamine (2) may be a useful alternative for pharmacological studies. The latter was obtained following catalytic O- debenzylation of 4-benzyloxy-N,N-dimethyltryptamine in the presence of acetic anhydride and sodium acetate.

Synthesis and in vitro evaluation of anti-inflammatory activity of ester and amine derivatives of indoline in RAW 264.7 and peritoneal macrophages

A prolonged increase in pro-inflammatory cytokines, TNF-α and IL-6 occurs in inflammatory diseases. Although existing therapies like steroids and TNF-α antagonists are effective they may cause serious adverse effects. We describe the preparation and evaluation for anti-inflammatory activity of 11 novel derivatives of indoline carbamates with a propionic ester, 2-aminoethyl, 3-aminopropyl 2-(dimethylamino)ethyl or 3-(dimethylamino)propyl group in positions 3 or 1. Compounds 25, 26 and 29 were previously shown to inhibit acetylcholinesterase with IC50s ranging from 0.4 to 55 μM and to prevent cytotoxicity induced by reactive oxygen species in a concentration range of 100 pM-1 μM. Compounds 25, 26, 29, 9, 10, 17 and 18, reduced NO, TNF-α and IL-6 at concentrations of 1-10 pM in LPS-activated RAW-264.7 and mouse peritoneal macrophages. The reduction in cytokines by compound 25 was associated with an increase in IκBα degradation and a decrease in the phosphorylation of p38 but not that of ERK. Conclusion: Indoline derivatives substituted at position 3 with chains carrying ester or amino groups may have potential for the treatment of chronic inflammatory and neurodegenerative diseases.